HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

FDA

Regulatory intelligence
FDAsafety guidance66% confidence

FDA AP — VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER (SUPPL)

Source: FDA

Why This Matters

Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Saptalis Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.

Regulatory Analysis

Application NDA050671. Sponsor: BAXTER HLTHCARE. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: VANCOMYCIN HYDROCHLORIDE.

Supporting Context

Therapeutic area
Neurology · Antihistamine
Sub-indication
General

Related signal: FDA Approves Hydroxyzine Hydrochloride ANDA220271 by Saptalis Pharmaceuticals

Source

View source document

Related Signal

Open signal — FDA Approves Hydroxyzine Hydrochloride ANDA220271 by Saptalis Pharmaceuticals
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.